Gabapentin Tablet, Film Coated
Product Images NDC 71335-1026

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An equation illustrating the formula for calculating creatinine clearance (CLCr). The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 applied for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin shown as a cyclohexane ring with side chains including an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H), illustrating the molecular framework of this active ingredient.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

Line graph depicting mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, with mean pain scores decreasing for gabapentin and remaining relatively stable for placebo across weeks.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph comparing mean pain scores over 7 weeks for placebo and Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis shows weeks including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. The data illustrates changes from baseline through the study period for the three groups.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) versus Gabapentin (GBP) at different doses across two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg. Study 2 shows 14% responders for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart comparing percentage difference versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. Daily doses on the x-axis range from 600 mg to 1800 mg, and percentage difference on the y-axis ranges from 2% to 22%. Each study is represented by distinct symbols with corresponding data points clustered by dose amount.*

FDA Label Image

Label (Lbl713351026)

Gabapentin 600 mg tablet label from Bryant Ranch Prepack, featuring comparison to Neurontin 600 mg tablets by Vivimed Life Sciences Pvt Ltd. The label includes storage instructions, a warning about dizziness, a lot number, barcode, and highlights the NDC 71335-1026. The tablet is described as a white oval.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.